Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

Next Previous
Search
Trial Profile

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DSG3-CAART (Primary) ; Resecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine; Immune globulin
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; First in man
  • Acronyms DesCAARTes; RESET-PV
  • Sponsors Cabaletta Bio

    • Most Recent Events

    • 13 Jan 2025 According to a Cabaletta Bio media release, company anticipates generate clinical and translational data evaluating rese-cel without preconditioning from the RESET-PV trial in 2025.
    • 13 Jan 2025 According to a Cabaletta Bio media release, As of December 31, 2024, 21 patients have been enrolled across 44 actively recruiting clinical sites in the U.S. and Europe across the RESET clinical development program.
    • 14 Nov 2024 According to a Cabaletta Bio media release, data from this study will be orally presented at ACR Convergence 2024 this coming weekend

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top